Expression level of pre-B-cell leukemia transcription factor 2 (PBX2) as a prognostic marker for gingival squamous cell carcinoma

Qiu, Ying; Wang, Zhu-ling; Jin, Shuqing; Pu, Yu-fei; Toyosawa, Satoru; Aozasa, Katsuyuki; Morii, Eiichi

doi:10.1631/jzus.b1100077

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Qiu et al showed that PBX2 was significantly upregulated in gingival squamous cell carcinoma (GSCC) samples, and its high expression was closely associated with poor disease‐free survival (DFS) ( p < 0.05) and OS ( p < 0.01). Furthermore, GSCC patients with low PBX2 expression showed a better OS ( p < 0.05) and DFS ( p < 0.001) rates compared to those with high expression at poor and moderate differentiations 112 . These data indicated that PBX2 expression possess great potential to be a new prognostic biomarker for GSCC.…”

Section: Clinical Applications Of Pbxs In Cancermentioning

confidence: 77%

The regulation of PBXs and their emerging role in cancer

Liu

Zhou

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Pre‐B‐cell leukaemia transcription factor (PBX) proteins are a subfamily of evolutionarily conserved, atypical homeodomain transcription factors that belong to the superfamily of three amino acid loop extension (TALE) homeodomain proteins. Members of the PBX family play crucial roles in regulating multiple pathophysiological processes, such as the development of organs, congenital cardiac defects and carcinogenesis. The dysregulation of PBXs has been shown to be closely associated with many diseases, particularly cancer. However, the detailed mechanisms of PBX dysregulation in cancer progression are still inconclusive. In this review, we summarize the recent advances in the structures, functions and regulatory mechanisms of PBXs, and discuss their underlying mechanisms in cancer progression. We also highlight the great potential of PBXs as biomarkers for the early diagnosis and prognostic evaluation of cancer as well as their therapeutic applications. The information reviewed here may expand researchers’ understanding of PBXs and could strengthen the clinical implication of PBXs in cancer treatment.

show abstract

Section: Clinical Applications Of Pbxs In Cancermentioning

confidence: 77%

The regulation of PBXs and their emerging role in cancer

Liu

Zhou

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…PBX2 has been reported to mediate the antiapoptotic function of miR-1915-3p in lung cancer (47). High expression of PBX2 has been identified as a poor prognostic indicator in gingival squamous cell carcinoma and non-small cell lung cancer (48,49). PBX3 has been suggested to be the target of multiple miRs, including miR-320a, miR-129-5p, and miR-526b, and mediates the antitumor effects of these miRs (50-52).…”

Section: Discussionmentioning

confidence: 99%

PBX1 is a valuable prognostic biomarker for patients with breast cancer

Ding

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Pre-B-cell leukemia transcription factor (PBX) proteins have important roles in the development of numerous organs. To date, four members of the PBX family have been identified to be involved in human cancer but little is known about their expression patterns and precise functions in breast cancer (BC) progression. The aim of the present study was to determine whether they have the potential to be prognostic biomarkers in patients with BC. The expression patterns of PBXs were evaluated using Oncomine, Cancer Cell Line Encyclopedia and Gene expression-based Outcome for Breast cancer Online algorithm analyses. The prognostic value of PBX1 was determined by Kaplan-Meier plotter analysis. It was observed that, among all PBX family members, only PBX1 was significantly upregulated in BC vs. normal tissues. Meta-analysis in the Oncomine database revealed that PBX1 was significantly upregulated in invasive breast carcinoma stroma, ductal breast carcinoma, invasive lobular breast carcinoma, invasive mixed breast carcinoma and male breast carcinoma compared with normal tissues. In addition, PBX1 was significantly correlated with forkhead box protein A1. Subtype analysis indicated that PBX1 overexpression was associated with luminal-like and hormone receptor-sensitive subtypes. In the survival analysis, a high expression level of PBX1 was associated with poor prognosis of patients with estrogen receptor (ER)-positive, luminal A and luminal B subtypes of BC. The results of the present study indicate that PBX1 may serve as a specific biomarker and essential prognostic factor for ER-positive, luminal A and luminal B subtypes of BC.

show abstract

“…One of the most prevalent cancers of the oral cavity is SCC. Expression pattern evaluation of Pbx2 (both mRNA and protein) in patients with gingival SCC (GSCC) revealed that Pbx2 was upregulated and could be a useful prognostic marker in these patients (Qiu et al, 2012). The overexpression of Pbx2 is associated with tumor size, stage, and metastasis, as well as a high expression of the valosincontaining protein (VCP) in GSCC cells (Qiu et al, 2012).…”

Section: Oral Cancermentioning

confidence: 99%

Oncogenic and tumor suppressor function of MEIS and associated factors

2020

View full text Add to dashboard Cite

MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer. MEIS and associated PBX-HOX proteins may act as tumor suppressors or oncogenes in different cellular settings. Their expressions tend to be misregulated in various cancers. Bioinformatic analyses have suggested their upregulation in leukemia/lymphoma, thymoma, pancreas, glioma, and glioblastoma, and downregulation in cervical, uterine, rectum, and colon cancers. However, every cancer type includes, at least, a subtype with high MEIS expression. In addition, studies have highlighted that MEIS proteins and associated factors may function as diagnostic or therapeutic biomarkers for various diseases. Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.

show abstract

Expression level of pre-B-cell leukemia transcription factor 2 (PBX2) as a prognostic marker for gingival squamous cell carcinoma

Cited by 8 publications

References 26 publications

The regulation of PBXs and their emerging role in cancer

The regulation of PBXs and their emerging role in cancer

PBX1 is a valuable prognostic biomarker for patients with breast cancer

Oncogenic and tumor suppressor function of MEIS and associated factors

Contact Info

Product

Resources

About